Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Oxford BioMedica plc    GB0006648157_GB   GB0006648157

OXFORD BIOMEDICA PLC (GB0006648157_GB)
My previous session
Most popular
  Report  
 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials (GBP)
Sales 2018 69,3 M
EBIT 2018 12,9 M
Net income 2018 9,57 M
Debt 2018 7,88 M
Yield 2018 -
Sales 2019 77,3 M
EBIT 2019 13,1 M
Net income 2019 10,6 M
Debt 2019 8,63 M
Yield 2019 -
P/E ratio 2018 59,07
P/E ratio 2019 54,77
EV / Sales2018 7,57x
EV / Sales2019 6,79x
Capitalization 516 M
More Financials
Company
Oxford Biomedica Plc is a biopharmaceutical company, which engages in the research and development of gene and cell therapy.The firm also provides bioprocessing and process development services to third parties.It operates through the Platform and Product segment.The Platform segment onsists of the... 
More about the company
Surperformance© ratings of Oxford BioMedica plc
Trading Rating : Investor Rating :
More Ratings
Latest news on OXFORD BIOMEDICA PLC
10/05OXFORD BIOMEDICA : announces additional details of its strategic alliance with O..
PU
10/05OXFORD BIOMEDICA : Details of alliance with Orchard Therapeutics
PU
09/21OXFORD BIOMEDICA : s expansion at former Royal Mail base
AQ
09/13Oxford biomedica plc interim results for the six months ended 30 june 2018
GL
09/13OXFORD BIOMEDICA : announces further capacity expansion with new facility
PU
09/13OXFORD BIOMEDICA : Interim Results
PU
09/13OXFORD BIOMEDICA : further capacity expansion
PU
09/13OXFORD BIOMEDICA : Interim results for the six months ended 30 June 2018
PU
09/10OXFORD BIOMEDICA PLC : half-yearly earnings release
08/28OXFORD BIOMEDICA : Kymriah® (tisagenlecleucel, formerly CTL019) recei..
PU
More news
Sector news : Bio Therapeutic Drugs
10/11GILEAD SCIENCES : Allogene's Upsized IPO Prices at High End of Range
DJ
10/05ABBVIE : Receives Health Canada Approval of Orilissa for Endometriosis Pain Trea..
DJ
10/04J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 billion
RE
10/02GILEAD SCIENCES : Allogene Sets IPO at 16 Million Shares; Sees Pricing $16-$18
DJ
09/28FDA Approves Libtayo to Treat Advanced Cutaneous Squamous Cell Carcinoma
DJ
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
03/16Oxford Biomedica PLC 2017 Q4 - Results - Earnings Call Slides 
2017Oxford Biomedica PLC reports 1H results 
2017The CTL019 Adcom Mists Begin To Clear 
2017Oxford BioMedica (OXBDF) Presents At Jefferies 2017 Global Healthcare Confere.. 
2017SNIPPET ROUNDUP : Novartis' Allogeneic CAR-T Drive And Astra's IL-4 Interest 
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 10,8  GBP
Spread / Average Target 38%
EPS Revisions
Managers
NameTitle
John Andrew Dawson Chief Executive Officer & Executive Director
Lorenzo M. Tallarigo Non-Executive Chairman
Nick Page Chief Operating Officer
Stuart Paynter Chief Financial Officer & Director
Kyriacos Mitrophanous Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
OXFORD BIOMEDICA PLC0.00%679
GILEAD SCIENCES2.72%93 985
VERTEX PHARMACEUTICALS20.99%44 892
REGENERON PHARMACEUTICALS2.18%39 451
NEUROCRINE BIOSCIENCES, INC.43.68%9 776
GENMAB-10.38%8 786